The use of medtech in empowering families within a complications of excess weight clinic: the evira® app

Karen Jackson; Maido Tsenoli; Malin Ramkloo; Lesley Swift; Claire Sower; Tracie Davies; Chamila Balagamage; Renuka Dias; Jan Idkowiak; Safia Ravat; Sarah Say

doi:10.1530/endoabs.111.OC8.1

OC8.1

Prev Next

Section Contents Cite

Endocrine Abstracts (2025) 111 OC8.1 | DOI: 10.1530/endoabs.111.OC8.1

BSPED2025 Oral Communications Endocrine Oral Communications 3 (5 abstracts)

The use of medtech in empowering families within a complications of excess weight clinic: the evira® app

Karen Jackson ^1,2 , Maido Tsenoli ^1,2,3 , Malin Ramkloo ³ , Lesley Swift ^1,2 , Claire Sower ⁴ , Tracie Davies ^1,2 , Chamila Balagamage ^1,2 , Renuka Dias ^1,2 , Jan Idkowiak ^1,2,5 , Safia Ravat ^1,2 & Sarah Say ^1,2

Author affiliations

¹Department of Endocrinology and Diabetes, Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; ²Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, University of Birmingham, Birmingham, United Kingdom; ³Evira, Stockholm, Sweden; ⁴Department of Paediatric Physiotherapy, Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham, United Kingdom; ⁵Department of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Birmingham, United Kingdom

Introduction: The West Midlands Complications of Excess Weight (CEW) clinic is an NHS England-funded pilot aimed at improving the health, well-being and quality of life of children and young people (CYP) living with weight-related health complications. A MedTech device (Evira®), consisting of a smartphone App and an electronic weight measurement scale, became available to our service in 2024 as a weight management intervention. It involves patients taking daily weight measurements, which are presented as a trend within the App to monitor individual progress. Instant messaging within the App enables frequent communication with families and the CEW team to encourage and reflect on progress together.

Method: The technology was discussed with all eligible patients in the CEW service and offered at every face-to-face contact. Patients and families were educated on the technology prior to commencing the intervention. All members of the CEW team were trained in monitoring the patient’s progress remotely and providing regular messaging to patients.

Results: Since May 2024, a total of 96 patients have started the intervention. For patients that have used Evira for 6 months (n = 44), there has been a mean average change of BMI z-score of –0.13 (SD ±0.03) compared to baseline. 23 patients paused or stopped using Evira within the first 6 months of treatment, mainly due to a lack of engagement or difficulty in sustaining changes. We have not encountered any significant technological barriers in our patient cohort.

Case Study: A 4-year-old child in our service was initially struggling to implement lifestyle changes. After introducing Evira, the CEW team sent encouraging messages and the patients BMI z-score reduced by 0.68 over 7 months.

Conclusion: The use of Evira MedTech empowers some patients within the CEW service to observe their progress on their weight loss journey and implement changes according to the direction of their trend. It also allows members of the CEW team to support families between clinic appointments and at a point in time when they require assistance. Enabling this frequent contact with the CEW team is particularly useful for families living far away from the hospital.